Biotech
§Signals
§ 02 Recent
Latest arrivals
FDA Approves First Gene Therapy for Deafness, Opening a New Chapter in Precision Medicine
Roche’s MS Candidate Fenebrutinib Shows Strong Efficacy Amid Safety Hurdles
Roche’s Multiple Sclerosis Ambitions Face a Critical Safety Test
Revolution Medicines and the Next Evolution of RAS Inhibition
The Immune System Reset: CAR-T Moves Beyond Cancer
A Hard-Won Six Months: KRAS Inhibition and the Future of Pancreatic Cancer Treatment
The Limits of Disruption: Senate Pushback on HHS Reorganization
Medicare’s Weight Loss Coverage Hits a Commercial Wall
Insurer Skepticism Stalls Trump’s Medicare Weight-Loss Pilot
§ 03 Editor's picks
- 01Biotech · STAT News (Biotech)
The Unlikely Alignment of the GOP and Psychedelics
A recent executive order marks the culmination of a Republican pivot toward psychedelic medicine, driven by veteran advocacy and a populist cultural shift.
- 02Biotech · STAT News (Biotech)
Cracking the Undruggable: A New Era for KRAS and Genetic Medicine
Recent breakthroughs in pancreatic cancer research and in-vivo CAR-T therapies signal a shift toward more precise, internal cellular engineering.
- 03Biotech · STAT News (Biotech)
A New Path to Immune Tolerance in Organ Transplants
A small study utilizing donor-derived cell therapy suggests a new way to train the immune system to accept transplanted organs without a lifetime of toxic drugs.
- 04Biotech · STAT News (Biotech)
Beyond GLP-1: A New Direction for Metabolic Medicine
Pioneering researchers are testing a provocative hypothesis: effective weight loss can be achieved by targeting GIP and glucagon hormones while bypassing the side-effect-prone GLP-1.
- 05Biotech · Endpoints News
A Warning on the Biotech Frontier
HHS Secretary Robert F. Kennedy Jr. warns Congress that China is outpacing the U.S. in drug approvals and clinical trials.
§ 05 By topic
In focus on this desk
UnitedHealth’s $1.5 Billion Bet on the Algorithmic Hospital
The healthcare giant is allocating massive capital to AI, aiming to streamline its internal bureaucracy while selling the same efficiency to its competitors.
The Laboratory State: Utah’s Experiment with the AI Physician
Endpoints NewsOpenAI Enters the Lab with GPT-Rosalind
Endpoints News
§ 06 More stories
12 of 60
Merck’s Ambitions for Welireg Stumble in First-Line Kidney Cancer Trial
A combination of Welireg and Keytruda failed to significantly improve outcomes for newly diagnosed patients, marking a hurdle for Merck’s oncology expansion.
The Pentagon Rescinds the Military’s Flu Vaccine Mandate
Defense Secretary Pete Hegseth cites medical autonomy and religious freedom in a move that shifts decades of military health protocol.
The Profit of Retrenchment at UnitedHealth
After years of aggressive expansion, the healthcare giant is finding financial success by narrowing its focus on Medicare Advantage and its provider networks.
A Turning Point for Pancreatic Cancer
Revolution Medicines’ daraxonrasib signals a potential shift in oncology, aiming to transform one of the most lethal cancers into a manageable, chronic condition.
The Physician-Senators Confronting RFK Jr.
As Robert F. Kennedy Jr. prepares for Senate confirmation hearings, four Republican physicians face the delicate task of balancing party loyalty with medical orthodoxy.
CAR-T Therapy Shows Early Success in Halting Pre-Cancerous Myeloma
A small study from the Dana-Farber Cancer Institute suggests that intervening with Carvykti before multiple myeloma fully develops could lead to complete remission.
The Constitutional Limits of the 25th Amendment
While critics point to erratic behavior as grounds for removal, the constitutional mechanism for presidential disability remains a high bar designed to prevent political upheaval.
The Formal Closing of the Purdue Pharma Chapter
A federal judge’s expected sentencing of the OxyContin manufacturer marks a procedural milestone in the effort to resolve thousands of opioid-related claims.
CMS Mandates State-Level Audits to Combat Healthcare Fraud
Administrator Mehmet Oz signals a more aggressive stance on provider verification, focusing on "high-risk" areas within federal programs.
The High-Stakes Resilience of Modern Biotech
Kelonia Therapeutics’ rise to a $3 billion valuation and BioAge’s new focus on inflammation underscore the volatile but lucrative path of drug development.
The Brief Tenure of Pfizer’s Strategist-in-Chief
Pfizer’s chief strategist departs after a brief tenure, signaling a potential shift in how drugmakers recruit from Wall Street, while Purdue Pharma nears a final settlement.
The CDC Closes a Door on Public Transparency
For decades, the agency’s scientific deliberations were open to all. A recent shift toward private meetings suggests a new, more guarded era for public health.